-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Overweight on Abivax, Raises Price Target to $175

Benzinga·07/09/2026 15:59:03
Listen to the news
Piper Sandler analyst Allison Bratzel maintains Abivax (NASDAQ:ABVX) with a Overweight and raises the price target from $165 to $175.